First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs.
The study, published in the Journal of Arthroplasty, highlighted that the Company’s NeuroCuple® Nanotechnology Device achieved statistically significant reduction in opioid use.
Build It Live at the HITLAB World Cup.
The DSMB review was conducted as part of the pre-planned clinical safety oversight process agreed upon with the U.S. FDA.
New 75,000-square-foot facility to open in October 2026 near Salt Lake City International Airport, extending company’s national reach for medical device manufacturers
The company’s comprehensive viral target atlas is designed to move development from reactive crisis response toward proactive, pre-identified genomic vulnerability mapping
nView medical announced that its nView s1 system has surpassed 1,000 surgeries, marking an important milestone in the clinical use of the company’s intraoperative 3D imaging and navigation technology.
University of Utah Launchpad Seed Fund award to support translational validation of NanoKar’s ITAM optimization platform, including CAR-T persistence and activity in solid tumor models.
Expanded collaboration adds manufacturing capacity, strengthens redundancy, and supports later-stage development planning for Ratio’s lead FAP-targeted radiotherapeutic candidate.
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally
Mosman to lead NanoKar’s next phase of translational validation, partner readiness, and strategic collaboration for its ITAM optimization platform